TY - JOUR
T1 - Cough-Specific Quality of Life Predicts Disease Progression Among Patients With Interstitial Lung Disease
T2 - Data From the Pulmonary Fibrosis Foundation Patient Registry
AU - Pulmonary Fibrosis Foundation
AU - Lee, Janet
AU - White, Emily
AU - Freiheit, Elizabeth
AU - Scholand, Mary Beth
AU - Strek, Mary E.
AU - Podolanczuk, Anna J.
AU - Patel, Nina M.
AU - Bascom, Rebecca
AU - Belloli, Elizabeth
AU - Bhatt, Nitin
AU - Bhorade, Sangeeta
AU - Case, Amy
AU - Castriotta, Richard
AU - Criner, Gerard
AU - Danoff, Sonye
AU - De Andrade, Joao
AU - Desai, Alpa
AU - Glassberg, Marilyn
AU - Glazer, Craig
AU - Gulati, Mridu
AU - Gupta, Nishant
AU - Hamblin, Mark
AU - Huie, Tristan
AU - Kaner, Robert
AU - Kass, Daniel
AU - Kim, Hyun
AU - Kreider, Maryl
AU - Lancaster, Lisa
AU - Lasky, Joseph
AU - Limper, Andrew
AU - Montesi, Sydney
AU - Mooney, Joshua
AU - Morrison, Lake
AU - Nambiar, Anoop
AU - Nathan, Steven
AU - Natt, Bhupinder
AU - Paul, Tessy
AU - Perez, Rafael
AU - Podolanczuk, Anna
AU - Raghu, Ganesh
AU - Shifren, Adrian
AU - Strek, Mary
AU - Todd, Nevins
AU - Walia, Rajat
AU - Weight, Stephen
AU - Whelan, Timothy
AU - Wolters, Paul
N1 - Funding Information:
Funding/support: This study was funded by the Pulmonary Fibrosis Foundation. A. P. is supported by the National Institutes of Health [Grant K23HL140199].
Funding Information:
Author contributions: N. M. P. is the guarantor of the manuscript and had final responsibility for all content of the manuscript. E. W. and E. F. performed the statistical analysis. J. L. wrote the first draft of the manuscript, and all authors critically reviewed, edited, and approved of the final version of the manuscript. Funding/support: This study was funded by the Pulmonary Fibrosis Foundation. A. P. is supported by the National Institutes of Health [Grant K23HL140199]. Financial/nonfinancial disclosures: The authors have reported to CHEST the following: M. B. S. is on the advisory board for Veracyte, Genentech, and United Therapeutics; is a speaker for Boehringer-Ingelheim, Veracyte, and United Therapeutics; and is a primary investigator for Boehringer-Ingelheim, Galapago, the National Institutes of Health, and Nitto Denko. A. P. is on the advisory board for Boehringer-Ingelheim and reports consulting fees from Regeneron, Roche, and Imvaria unrelated to the submitted work. M. E. S. is a primary investigator for institutional studies with Boehringer Ingelheim, Galapagos, and the National Institutes of Health; reports involvement with Boehringer Ingelheim medical writing assistance; and is a member of the Fibrogen Endpoint Adjudication Committee. N. M. P. is employed at Boehringer-Ingelheim. None declared (J. L. E. W. E. F.). Role of sponsors: The Pulmonary Fibrosis Foundation had no role in the design of the study. The University of Michigan Statistical Analysis of Biomedical and Educational Research unit served as the registry data coordinating center and managed data entered by registry sites. Statistical analysis of the data was performed by the University of Michigan Statistical Analysis of Biomedical and Educational research unit, as well as preparation of the statistical methods and tables for the manuscript. Collaborators from the Pulmonary Fibrosis Foundation: Pulmonary Fibrosis Foundation Care Center Network site principal investigators: Rodeo Abrenchillo, MD; Rebecca Bascom, MD; Elizabeth Belloli, MD; Nitin Bhatt, MD; Amy Case, MD; Sachin Chaudhary, MD; Gerard Criner, MD; Alpa Desai, MD; Christine Garcia, MD; Craig Glazer, MD; Mridu Gulati, MD; Nishant Gupta, MD; Mark Hamblin, MD; Tristan Huie, MD; Robert Kaner, MD; Daniel Kass, MD; Hyun Kim, MD; Christopher King, MD; Robert Matthew Kottman, MD; Lisa Lancaster, MD; Joseph Lasky, MD; Andrew Limper, MD; Tracy Luckhardt, MD; Sydney Montesi, MD; Joshua Mooney, MD; Lake Morrison, MD; Anoop Nambiar, MD; Rafael Perez, MD; Mary Porteous, MD; Mary Beth Scholand, MD; Adrian Shifren, MD; Danoff Sonye, MD; Mary Strek, MD; Paul Tessy, MD; Nevins Todd, MD; Rade Tomic, MD; Rajat Walia, MD; Stephen Weight, MD; Timothy Whelan, MD; and Paul Wolters, MD.
Publisher Copyright:
© 2022 American College of Chest Physicians
PY - 2022/9
Y1 - 2022/9
N2 - Background: Cough is a common symptom of interstitial lung disease (ILD) and negatively impacts health-related quality of life (QOL). Previous studies have shown that among patients with idiopathic pulmonary fibrosis, cough may predict progression of lung disease and perhaps even respiratory hospitalizations and mortality. Research Question: Does cough-specific QOL predict disease progression, respiratory hospitalization, lung transplantation, and death among patients with ILD? Study Design and Methods: We analyzed data from the Pulmonary Fibrosis Foundation Registry, which comprises a multicenter population of well-characterized patients with ILD. We first examined associations between patient factors and baseline scores on the Leicester Cough Questionnaire (LCQ), a cough-specific QOL tool, using a proportional odds model. Next, we examined associations between baseline LCQ scores and patient-centered clinical outcomes, as well as pulmonary function parameters, using a univariable and multivariable proportional hazards model that was adjusted for clinically relevant variables, including measures of disease severity. Results: One thousand four hundred forty-seven patients with ILD were included in our study. In the multivariable proportional odds model, we found that the following patient factors were associated with worse cough-specific QOL: younger age, diagnosis of “other ILD,” gastroesophageal reflux disease, and lower FVC % predicted. Multivariable Cox regression models, adjusting for several variables including baseline disease severity, showed that a 1-point decrease in LCQ score (indicating lower cough-specific QOL) was associated with a 6.5% higher risk of respiratory-related hospitalization (hazard ratio [HR], 1.065; 95% CI, 1.025-1.107), a 7.4% higher risk of death (HR, 1.074; 95% CI, 1.020-1.130), and an 8.7% higher risk of lung transplantation (HR, 1.087; 95% CI, 1.022-1.156). Interpretation: Among a large population of well-characterized patients with ILD, cough-specific QOL was associated independently with respiratory hospitalization, death, and lung transplantation.
AB - Background: Cough is a common symptom of interstitial lung disease (ILD) and negatively impacts health-related quality of life (QOL). Previous studies have shown that among patients with idiopathic pulmonary fibrosis, cough may predict progression of lung disease and perhaps even respiratory hospitalizations and mortality. Research Question: Does cough-specific QOL predict disease progression, respiratory hospitalization, lung transplantation, and death among patients with ILD? Study Design and Methods: We analyzed data from the Pulmonary Fibrosis Foundation Registry, which comprises a multicenter population of well-characterized patients with ILD. We first examined associations between patient factors and baseline scores on the Leicester Cough Questionnaire (LCQ), a cough-specific QOL tool, using a proportional odds model. Next, we examined associations between baseline LCQ scores and patient-centered clinical outcomes, as well as pulmonary function parameters, using a univariable and multivariable proportional hazards model that was adjusted for clinically relevant variables, including measures of disease severity. Results: One thousand four hundred forty-seven patients with ILD were included in our study. In the multivariable proportional odds model, we found that the following patient factors were associated with worse cough-specific QOL: younger age, diagnosis of “other ILD,” gastroesophageal reflux disease, and lower FVC % predicted. Multivariable Cox regression models, adjusting for several variables including baseline disease severity, showed that a 1-point decrease in LCQ score (indicating lower cough-specific QOL) was associated with a 6.5% higher risk of respiratory-related hospitalization (hazard ratio [HR], 1.065; 95% CI, 1.025-1.107), a 7.4% higher risk of death (HR, 1.074; 95% CI, 1.020-1.130), and an 8.7% higher risk of lung transplantation (HR, 1.087; 95% CI, 1.022-1.156). Interpretation: Among a large population of well-characterized patients with ILD, cough-specific QOL was associated independently with respiratory hospitalization, death, and lung transplantation.
KW - Leicester cough questionnaire
KW - cough
KW - disease progression
KW - health-related quality of life
KW - idiopathic pulmonary fibrosis
KW - interstitial lung disease
KW - mortality
UR - http://www.scopus.com/inward/record.url?scp=85136361918&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85136361918&partnerID=8YFLogxK
U2 - 10.1016/j.chest.2022.03.025
DO - 10.1016/j.chest.2022.03.025
M3 - Article
C2 - 35337809
AN - SCOPUS:85136361918
SN - 0012-3692
VL - 162
SP - 603
EP - 613
JO - CHEST
JF - CHEST
IS - 3
ER -